The Current Regulatory Landscape For Obesity Drugs 

Skye Bioscience’s Putin Dhillon describes how next-generation obesity drug developers must prove to regulators that their products do not carry a risk of neuropsychiatric side effects.
An excerpt from "Obesity Tx End-Around With Skye Bioscience's Punit Dhillon" - check out the full video at www.bioprocess...
---
#businessofbiotech #biopharma #biotech
Subscribe to the podcast:
Apple - podcasts.apple...
Spotify - open.spotify.c...
RU-vid - • The Business Of Biotec...